The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo.
<h4>Unlabelled</h4>Pharmacologically-induced activation of replication competent proviruses from latency in the presence of antiretroviral treatment (ART) has been proposed as a step towards curing HIV-1 infection. However, until now, approaches to reverse HIV-1 latency in humans have yi...
Main Authors: | Ole S Søgaard, Mette E Graversen, Steffen Leth, Rikke Olesen, Christel R Brinkmann, Sara K Nissen, Anne Sofie Kjaer, Mariane H Schleimann, Paul W Denton, William J Hey-Cunningham, Kersten K Koelsch, Giuseppe Pantaleo, Kim Krogsgaard, Maja Sommerfelt, Remi Fromentin, Nicolas Chomont, Thomas A Rasmussen, Lars Østergaard, Martin Tolstrup |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-09-01
|
Series: | PLoS Pathogens |
Online Access: | https://doi.org/10.1371/journal.ppat.1005142 |
Similar Items
-
Immune checkpoints and the HIV-1 reservoir: proceed with caution
by: Rikke Olesen, et al.
Published: (2016-07-01) -
Romidepsin in the treatment of cutaneous T-cell lymphoma
by: Jain S, et al.
Published: (2011-04-01) -
Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency ex vivo without T cell activation
by: Jesper D. Gunst, et al.
Published: (2019-07-01) -
Pharmacokinetics and Immunological Effects of Romidepsin in Rhesus Macaques
by: Adam J. Kleinman, et al.
Published: (2020-12-01) -
Peripheral T cell lymphoma: clinical utility of romidepsin
by: Sawey K, et al.
Published: (2012-06-01)